Investment into vaccines based on broadly neutralising antibodies could allow pan-virus vaccines to be developed and stockpiled before the next pandemic, say researchers.
Gilead Sciences has released a statement regarding the efficacy of its antiviral treatment Veklury (remdesivir), maintaining confidence in the its continued benefit against new COVID-19 variants.
New research suggests that Pfizer/BioNTech’s mRNA Covid-19 vaccine, BNT162b2, protects against two variants of SARS-CoV-2, the virus that causes Covid-19, that have emerged in the UK and South Africa.